Inventor · disambiguated record
Marcelo Bigal
Also filed as: BIGAL MARCELO
8 granted patents·10 pending applications·29 citations·filing 2015–2024
85Inventor score
Files withTEVA PHARMACEUTICALS INT GMBH18
Top patents by PatentIndex Score
18 records- 0193US11028160B2Treating refractory migraineTEVA PHARMACEUTICALS INT GMBH·Filed 2020·Granted Jun 8, 2021·4 cites·30 claims
- 0290US11028161B2Treating refractory migraineTEVA PHARMACEUTICALS INT GMBH·Filed 2020·Granted Jun 8, 2021·2 cites·30 claims
- 0388US10519224B2Treating headache comprising administering an antibody to calcitonin gene-related peptideTEVA PHARMACEUTICALS INT GMBH·Filed 2018·Granted Dec 31, 2019·7 cites·23 claims
- 0488US10392434B2Treating refractory migraineTEVA PHARMACEUTICALS INT GMBH·Filed 2017·Granted Aug 27, 2019·4 cites·13 claims
- 0588US9896502B2Antagonist antibodies directed against calcitonin gene-related peptide and methods using sameTEVA PHARMACEUTICALS INT GMBH·Filed 2015·Granted Feb 20, 2018·8 cites·20 claims
- 0687US2025263474A1Treating refractory migraineTEVA PHARMACEUTICALS INT GMBH·Filed 2024·Application pending·0 cites
- 0784US10556945B2Antagonist antibodies directed against calcitonin gene-related peptide and methods using sameTEVA PHARMACEUTICALS INT GMBH·Filed 2015·Granted Feb 11, 2020·3 cites·19 claims
- 0882US12139528B2Treating refractory migraineTEVA PHARMACEUTICALS INT GMBH·Filed 2023·Granted Nov 12, 2024·0 cites·19 claims
- 0980US11555064B2Treating headache comprising administering an antibody to calcitonin gene-related peptideTEVA PHARMACEUTICALS INT GMBH·Filed 2019·Granted Jan 17, 2023·1 cites·43 claims
- 1073US2022098287A1Treating refractory migraineTEVA PHARMACEUTICALS INT GMBH·Filed 2021·Application pending·0 cites
- 1172US2023235032A1Antagonist Antibodies Directed Against Calcitonin Gene-Related Peptide and Methods Using SameTEVA PHARMACEUTICALS INT GMBH·Filed 2022·Application pending·0 cites
- 1268US2020223911A1Treating refractory migraineTEVA PHARMACEUTICALS INT GMBH·Filed 2019·Application pending·0 cites
- 1367US2020148761A1Preventing, treating, and reducing (persistent) post-traumatic headacheTEVA PHARMACEUTICALS INT GMBH·Filed 2019·Application pending·0 cites
- 1466US2022048986A1Preventing, treating, and reducing (persistent) post-traumatic headacheTEVA PHARMACEUTICALS INT GMBH·Filed 2021·Application pending·0 cites
- 1559US2020102377A1Treating cluster headacheTEVA PHARMACEUTICALS INT GMBH·Filed 2019·Application pending·0 cites
- 1658US2020377581A1Antagonist Antibodies Directed Against Calcitonin Gene-Related Peptide and Methods Using SameTEVA PHARMACEUTICALS INT GMBH·Filed 2019·Application pending·0 cites
- 1749US2018111984A1Treating cluster headacheTEVA PHARMACEUTICALS INT GMBH·Filed 2017·Application pending·0 cites
- 1849US2017088612A1Preventing, treating, and reducing (persistent) post-traumatic headacheTEVA PHARMACEUTICALS INT GMBH·Filed 2016·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →